Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

IVIG for Alzerheimer’s: Cost is a barrier

Matthew Mintz, MD
Meds
July 31, 2012
Share
Tweet
Share

Media outlets are reporting the results of a small, but very important study regarding a new treatment for Alzheimer’s Disease.  Most Americans are familiar with Alzheimer’s because it is so common (President Reagan had it), so devastating, and without a cure.  This new study gives hope to people who have or are at risk for the disease.

Recently at the Alzheimer’s Association International Conference 2012 in Vancouver, researchers presented the positive results of a study using intravenous immunoglobulin, or IVIG, to successfully keep Alzheimer’s disease at bay.  Controversy exists because the study was very small (16 patients total), of which 11 patients took IVIG for three years and showed improvement thinking, memory, daily functions and mood.

Immunoglobulins are part of the human immune system.  They are made naturally and help ward of a variety of infections and disease. IVIG has been used to treat a variety of auto-immune disease. Though no one is 100% sure how IVIG works, it is though to have antibodies against amyloid.  Amyloid is a protein which accumulates in the brains of patients who who have Alzheimer’s.

Though most experts caution current use in the general public and are clear that more research is needed, many believe this is a very good sign indeed.

However, let’s assume that the research is proven correct, and that IVIG actually does work well for most patients to treat Alzheimer’s disease.  One of the problems is that IVIG is not cheap.  Since it is a blood product it is expensive- you need to get it from human donors, you need a nurse to administer it, and it must be given in a doctor’s office or hospital. It is given once every two weeks, with an estimated to cost a patient $2,000 to $5,000.

According to data from Alzheimer’s Association, there are 5.4 millions American’s with Alzheimer’s. If we take the low estimate of $2000 every other week, it would cost $280 billion each year to treat patients with Alzheimer’s. In 2012, the direct costs of caring for those with Alzheimer’s to American society will total an estimated $200 billion, including $140 billion in costs to Medicare and Medicaid.  Essentially what this means is that it would cost nearly $100 billion dollars more each year to treat patients with IVIG and prevent Alzheimer’s progression, than to simply treat this very expensive disease.

Though in some instances, like vaccines, an ounce of prevention is worth a pound of cure.  However, in many examples, medical treatment is very expensive and keeping people alive and well cost more in the long run. It is our skyrocketing health care costs that plague our health care system and if we don’t fix the problem soon, it could bankrupt our country.  Resources are not limitless.  Since much of our health care is funded with taxpayer dollars, we as a society are going to have to make some very important decisions.

If we decide that we think it is worth paying for everyone who has Alzheimer’s to get IVIG for example, we are going to need to decide what we are not going to pay for to keep costs down.  These are difficult decisions.  The problem is that these types of conversations or not really happening today because the health care debate has become more about who will be the next President than actually solving our country’s problems.

Matthew Mintz is an internal medicine physician who blogs at Dr. Mintz’ Blog.

Prev

Doctors avoid comprehensive preventative questioning

July 31, 2012 Kevin 1
…
Next

Mainstream media's sinister undertone against doctors

July 31, 2012 Kevin 12
…

Tagged as: Medications, Neurology

Post navigation

< Previous Post
Doctors avoid comprehensive preventative questioning
Next Post >
Mainstream media's sinister undertone against doctors

ADVERTISEMENT

More by Matthew Mintz, MD

  • a desk with keyboard and ipad with the kevinmd logo

    Primary care trends in the health reform era

    Matthew Mintz, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Is there a harm to not seeing drug reps?

    Matthew Mintz, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Using Advair to treat postinfectious cough

    Matthew Mintz, MD

More in Meds

  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Why AI in health care needs stronger testing before clinical use [PODCAST]

      The Podcast by KevinMD | Podcast
    • How AI is reshaping preventive medicine

      Jalene Jacob, MD, MBA | Tech
    • How transplant recipients can pay it forward through organ donation

      Deepak Gupta, MD | Physician
    • Inside the high-stakes world of neurosurgery

      Isaac Yang, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Why AI in health care needs stronger testing before clinical use [PODCAST]

      The Podcast by KevinMD | Podcast
    • How AI is reshaping preventive medicine

      Jalene Jacob, MD, MBA | Tech
    • How transplant recipients can pay it forward through organ donation

      Deepak Gupta, MD | Physician
    • Inside the high-stakes world of neurosurgery

      Isaac Yang, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...